Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 23;11(4):367-377.
doi: 10.1093/ehjqcco/qcae038.

Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors

Bénédicte Manderlier  1   2 , Berlinde von Kemp  1 , Katrien Beeckman  2 , Bernard Cosyns  1 , Karen Van den Bussche  1   2 ; cardio-oncology expert panel
Collaborators, Affiliations

Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors

Bénédicte Manderlier et al. Eur Heart J Qual Care Clin Outcomes. .

Abstract

Aims: There is an increasing awareness of the evidence-based selection of outcomes to be measured in clinical trials and clinical practice. Currently, there is no core outcome set (COS) for cardio-oncology, which may hinder the (inter)national comparison of the effectiveness of research and the quality of cardio-oncology care. The aim of this study is to develop a standard and pragmatic patient-centred outcome set to assess and monitor cancer patients and survivors at risk of or with cardiovascular diseases.

Methods and results: A list of outcome domains was generated through a review of registries and guidelines, and six patient interviews. The project team reviewed and refined the outcome domains prior to starting a two-round Delphi procedure conducted between January and June 2022. The panellists, including healthcare providers and researchers, were invited to rate the importance of the outcomes. Twenty-six experts from 11 countries rated a list of 93 outcomes (round 1) and 63 outcomes (round 2) to gain consensus on a list of outcome measures, and of demographic factors, health status, and treatment variables. The final COS includes 15 outcome measures, reflecting four core areas: life impact (n = 2), pathophysiological manifestations (n = 9), resource use/economic impact (n = 1), and mortality/survival (n = 3). Next, 6 demographic factors, 21 health status, 3 cardiovascular, and 9 cancer variables were included.

Conclusions: This is the first international development of a COS for cardio-oncology. This set aims to facilitate (inter)national comparison in cardio-oncology care, using standardized parameters and meaningful patient-centred outcomes for research and quality of care assessments.

Keywords: Cardio-oncology; Core outcome set; Outcome measure; Patient registry; Patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Development process of the core outcome set for cardio-oncology.
Figure 2
Figure 2
Demographic factors, health status, and treatment variables to be considered for risk adjustment when measuring cardio-oncology outcomes.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sase K, Kida K, Furukawa Y. Cardio-oncology rehabilitation-challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors. J Cardiol 2020;76:559–567. - PubMed
    1. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019;139:e997–e1012. - PMC - PubMed
    1. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem J-E, Barlesi F et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc 2020;9:e018403. - PMC - PubMed
    1. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 2016;66:309–325. - PubMed
    1. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:1720–1729. - PubMed